ANI Pharmaceuticals Q2 2025 Earnings Report

ANI Pharmaceuticals EPS Results

• Actual EPS: $1.80
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

ANI Pharmaceuticals Revenue Results

• Actual Revenue: $211.37 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

ANI Pharmaceuticals Announcement Details

• Quarter: Q2 2025
• Date: 9/8/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

ANI Pharmaceuticals (NASDAQ:ANIP) is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care. Alongside its proprietary generics business, ANI provides contract development and manufacturing organization (CDMO) services, leveraging its integrated in-house capabilities in sterile and nonsterile production, analytical testing and regulatory support to meet the needs of pharmaceutical partners.

Primarily serving markets in North America, ANI maintains multiple U.S. manufacturing facilities certified for complex sterile and nonsterile operations. The company collaborates with major distributors, retail pharmacies, hospitals and healthcare systems, and continues to invest in process optimization and quality systems to expand its product pipeline and support evolving patient needs.